Article Sidebar

PDF
Date Published: 27/10/2023
Abstract Views: 155
Views PDF: 135
DOI: https://doi.org/10.56535/jmpm.v48i8.446
Issue
Vol. 48 No. 8 (2023): TẠP CHÍ Y DƯỢC HỌC QUÂN SỰ SỐ 8 - 2023
Section
Articles
How to Cite
Nguyễn, T. P., Phùng, T. H., Nguyễn, H. P., Nguyễn, N. T., Hoàng, T. K., Lê, V., Đỗ, A. T., Lê, V. Đ., & Đỗ, K. Đ. (2023). A PROTOCOL FOR THE PURIFICATION AND EXPANSION OF PERIPHERAL BLOOD NATURAL KILLER CELLS DERIVED FROM PROSTATE CANCER PATIENTS. Journal of Military Pharmaco-medicine, 48(8), 16-25. https://doi.org/10.56535/jmpm.v48i8.446

A PROTOCOL FOR THE PURIFICATION AND EXPANSION OF PERIPHERAL BLOOD NATURAL KILLER CELLS DERIVED FROM PROSTATE CANCER PATIENTS

Nguyễn Trọng Phúc, Thế Hải Phùng, Hoàng Phương Nguyễn, Ngọc Tuấn Nguyễn, Trung Kiên Hoàng, Việt Lê, Anh Tuấn Đỗ, Văn Đông Lê, Khắc Đại Đỗ1,
1 dokhacdai@vmmu.edu.vn

Main Article Content

Abstract

Objectives: To establish a protocol for the purification and expansion of Natural Killer cells (NK cells) derived from prostate cancer patients in vitro. Methods: We collected peripheral blood samples from 3 patients diagnosed with prostate cancer for peripheral blood mononuclear cells (PBMCs) separation and generated high-purity NK cells by using Microbeads (Miltenyi/Germany) from the PBMCs (day 0 - D0). The NK cells were cultured in a KBM-specific medium (Kohjin-Bio/Japan) for expansion and harvested on day 14 (D14). Results: The purification rate of  NK cells was 93.4% on day D0 and 94.9% on day D14. The average number of harvested NK cells at D14 was 385.3 x 106 cells (which increased by 192.7 times than that of day D0). Conclusion: We have successfully established and implemented successfully the process of purifying and culturing NK cells in prostate cancer patients.

Article Details

Keywords

Prostate cancer, NK cells, Purification process, Proliferation process

References

1. K. Nagai, Y. Harada, H. Harada, K. Yanagihara, Y. Yonemitsu, Y. Miyazaki. Highly activated ex vivo-expanded natural killer cells in patients with solid tumors in a phase I/IIa clinical study. Anticancer Res. 2020 Oct; 40(10):5687-5700.
2. V. Dedeepiya, H. Terunuma, S. Manjunath, R. Senthilkumar, P. Thamaraikannan, T. Srinivasan, C. HelenReena, S. Preethy, S. Abraham. Autologous immune enhancement therapy for cancer using NK cells and CTLs without feeder layers; our six year experience in India. J Stem Cells Regen Med. 2011 Oct 30; 7(2):95.
3. C. Pasero, G. Gravis, M. Guerin, S. Granjeaud, J. Thomassin-Piana, P. Rocchi, M. Paciencia-Gros, F. Poizat, M. Bentobji, F. Azario-Cheillan, J. Walz, N. Salem, S. Brunelle, A. Moretta, D. Olive. Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity. Cancer Res. 2016 Apr 15; 76(8):2153-2165.
4. S. PaµL, G. Lal. The MolecµLar mechanism of natural killer cells function and its importance in cancer immunotherapy. Front Immunol. 2017 Sep 13; 8:1124.
5. M. Berg,. et al. Ex-vivo expansion of NK cells: What is the priority - high yield or high purity? Cytotherapy. 2010; 12:969-970.
6. K. Nagai,. et al. Highly activated ex vivo-expanded natural killer cells in patients with solid tumors in a phase I/IIa clinical study. ANTICANCER RESEARCH. 2020; 40:5687-5700.
7. F. Wang,. et al. Allogeneic expanded human peripheral NK cells control prostate cancer growth in a preclinical mouse model of castration-resistant prostate cancer. Hindawi Journal of Immunology Research. 2022. Article ID 1786395.
8. R. Somayeh,. et al. Autologous natural killer cell-enrichment for immune cell therapy: Preclinical setting phase, shiraz experience. Iran J Allergy Asthma Immunol. 2021. 20(2):233-243.
9. N. Sakamoto, T. Ishikawa, S. Kokura, et al. Phase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancer. J Transl Med. 2015; 13:277.
10. B. Subramani, CR. Pullai, K. Krishnan, SD. Sugadan, X. Deng, T Hiroshi, K. Ratnavelu. Efficacy of ex vivo activated and expanded natural killer cells and T lymphocytes for colorectal cancer patients. Biomed Rep. 2014 Jul; 2(4):505-508.